Bellicum Pharmaceuticals Inc (BLCM) Holdings Cut by Mcdaniel Terry & Co.

Mcdaniel Terry & Co. trimmed its position in Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) by 33.4% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 23,900 shares of the biopharmaceutical company’s stock after selling 12,000 shares during the period. Mcdaniel Terry & Co. owned about 0.07% of Bellicum Pharmaceuticals worth $201,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of BLCM. Franklin Street Advisors Inc. NC grew its position in shares of Bellicum Pharmaceuticals by 293.0% during the 4th quarter. Franklin Street Advisors Inc. NC now owns 48,285 shares of the biopharmaceutical company’s stock valued at $406,000 after acquiring an additional 36,000 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Bellicum Pharmaceuticals during the 3rd quarter valued at approximately $164,000. Point72 Asset Management L.P. bought a new position in shares of Bellicum Pharmaceuticals during the 3rd quarter valued at approximately $4,723,000. Schwab Charles Investment Management Inc. grew its position in shares of Bellicum Pharmaceuticals by 47.1% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 131,217 shares of the biopharmaceutical company’s stock valued at $1,516,000 after acquiring an additional 41,995 shares during the period. Finally, Harvey Capital Management Inc. bought a new position in shares of Bellicum Pharmaceuticals during the 3rd quarter valued at approximately $458,000. 55.21% of the stock is owned by institutional investors and hedge funds.

BLCM has been the subject of a number of research reports. Zacks Investment Research downgraded shares of Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, January 12th. SunTrust Banks reduced their target price on shares of Bellicum Pharmaceuticals to $18.00 and set a “buy” rating for the company in a research report on Wednesday, January 31st. Raymond James Financial reissued a “buy” rating on shares of Bellicum Pharmaceuticals in a research report on Tuesday, December 12th. ValuEngine raised shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd. Finally, BidaskClub downgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 11th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $16.88.

In related news, major shareholder Bros. Advisors Lp Baker sold 880,735 shares of the firm’s stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $8.20, for a total value of $7,222,027.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Alan A. Musso sold 17,117 shares of the firm’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $9.33, for a total transaction of $159,701.61. Following the completion of the transaction, the chief financial officer now directly owns 31,585 shares of the company’s stock, valued at $294,688.05. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,165,145 shares of company stock valued at $9,696,662. 18.77% of the stock is owned by insiders.

Bellicum Pharmaceuticals Inc (BLCM) opened at $5.97 on Friday. The company has a market cap of $198.53, a P/E ratio of -2.00 and a beta of 0.70. Bellicum Pharmaceuticals Inc has a fifty-two week low of $5.02 and a fifty-two week high of $15.55. The company has a quick ratio of 6.08, a current ratio of 6.08 and a debt-to-equity ratio of 0.23.

ILLEGAL ACTIVITY WARNING: “Bellicum Pharmaceuticals Inc (BLCM) Holdings Cut by Mcdaniel Terry & Co.” was first reported by Week Herald and is the sole property of of Week Herald. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://weekherald.com/2018/02/16/bellicum-pharmaceuticals-inc-blcm-holdings-cut-by-mcdaniel-terry-co.html.

Bellicum Pharmaceuticals Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Want to see what other hedge funds are holding BLCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bellicum Pharmaceuticals Inc (NASDAQ:BLCM).

Institutional Ownership by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply